Stopping the invasion

How targeting the IRF3 pathway could prevent GBM recurrence

A team from the Netherlands Cancer Institute (NKI) has identified a network of extracellular matrix proteins that drives glioblastoma invasiveness and a master switch -- interferon regulatory factor 3 (IRF3) -- that can turn it off. The group believes combining IRF3 activation with standard of care could prevent recurrence.

In a Cell Reports study in July, the NKI team, led by Olaf van Tellingen and René

Read the full 668 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE